Paul Hastings Advised Jefferies on Esperion Therapeutics' $85.1M Public Offering
January 19, 2024
January 19, 2024
LOS ANGELES, California, Jan. 19 -- Paul Hastings, a law firm, issued the following news:
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.'s, (Nasdaq: ESPR) $85.1 million public offering of common stock. In addition, Esperion granted Jefferies a 30-day option to purchase additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
Esperion is a pha . . .
Paul Hastings LLP advised Jefferies LLC as sole book running manager in connection with Esperion Therapeutics, Inc.'s, (Nasdaq: ESPR) $85.1 million public offering of common stock. In addition, Esperion granted Jefferies a 30-day option to purchase additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
Esperion is a pha . . .